Automated classification of PET-CT lesions in lung cancer: An independent validation study

Clin Physiol Funct Imaging. 2022 Sep;42(5):327-332. doi: 10.1111/cpf.12773. Epub 2022 Jul 7.

Abstract

Introduction: Recently, a tool called the positron emission tomography (PET)-assisted reporting system (PARS) was developed and presented to classify lesions in PET/computed tomography (CT) studies in patients with lung cancer or lymphoma. The aim of this study was to validate PARS with an independent group of lung-cancer patients using manual lesion segmentations as a reference standard, as well as to evaluate the association between PARS-based measurements and overall survival (OS).

Methods: This study retrospectively included 115 patients who had undergone clinically indicated (18F)-fluorodeoxyglucose (FDG) PET/CT due to suspected or known lung cancer. The patients had a median age of 66 years (interquartile range [IQR]: 61-72 years). Segmentations were made manually by visual inspection in a consensus reading by two nuclear medicine specialists and used as a reference. The research prototype PARS was used to automatically analyse all the PET/CT studies. The PET foci classified as suspicious by PARS were compared with the manual segmentations. No manual corrections were applied. Total lesion glycolysis (TLG) was calculated based on the manual and PARS-based lung-tumour segmentations. Associations between TLG and OS were investigated using Cox analysis.

Results: PARS showed sensitivities for lung tumours of 55.6% per lesion and 80.2% per patient. Both manual and PARS TLG were significantly associated with OS.

Conclusion: Automatically calculated TLG by PARS contains prognostic information comparable to manually measured TLG in patients with known or suspected lung cancer. The low sensitivity at both the lesion and patient levels makes the present version of PARS less useful to support clinical reading, reporting and staging.

Keywords: artificial intelligence; computer-based methods; image analysis; quantification; survival analysis.

MeSH terms

  • Aged
  • Fluorodeoxyglucose F18
  • Humans
  • Lung Neoplasms* / diagnostic imaging
  • Lung Neoplasms* / pathology
  • Middle Aged
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography* / methods
  • Prognosis
  • Radiopharmaceuticals
  • Retrospective Studies

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18